Farber HW - Search Results

1

Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol.

Gionfriddo WJ, Ahmed HN, Farber HW. Gionfriddo WJ, et al. Among authors: farber hw. JACC Case Rep. 2020 Feb 5;2(2):289-293. doi: 10.1016/j.jaccas.2019.10.040. eCollection 2020 Feb. JACC Case Rep. 2020. PMID: 34317225 Free PMC article.

2

Pulmonary Tumor Thrombotic Microangiopathy as a Cause of Pulmonary Hypertension.

Schwartz BP, Tracy P, Hon S, Farber HW, Udelson JE. Schwartz BP, et al. Among authors: farber hw. JACC Case Rep. 2021 Jul 7;3(7):1029-1031. doi: 10.1016/j.jaccas.2021.04.013. eCollection 2021 Jul 7. JACC Case Rep. 2021. PMID: 34317678 Free PMC article.

3

Epoprostenol-associated ascites in pulmonary arterial hypertension.

Schoenberg NC, Ruopp NF, Parikh RD, Farber HW. Schoenberg NC, et al. Among authors: farber hw. Pulm Circ. 2022 Jun 7;12(2):e12092. doi: 10.1002/pul2.12092. eCollection 2022 Apr. Pulm Circ. 2022. PMID: 35795488 Free PMC article.

4

Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.

Aguilar RV, Farber HW. Aguilar RV, et al. Among authors: farber hw. Am J Respir Crit Care Med. 2000 Nov;162(5):1846-50. doi: 10.1164/ajrccm.162.5.2004042. Am J Respir Crit Care Med. 2000. PMID: 11069824

5

Pharmacokinetics of ambrisentan in a patient with Pulmonary Arterial Hypertension and a total gastrectomy.

Abston E, Farber HW. Abston E, et al. Among authors: farber hw. Pulm Pharmacol Ther. 2019 Aug;57:101813. doi: 10.1016/j.pupt.2019.101813. Epub 2019 Jun 12. Pulm Pharmacol Ther. 2019. PMID: 31199984

6

Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension.

Abston E, Moll M, Hon S, Govender P, Berman J, Farber H. Abston E, et al. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(2):184-191. doi: 10.36141/svdld.v37i2.9150. Epub 2020 Jun 30. Sarcoidosis Vasc Diffuse Lung Dis. 2020. PMID: 33093782 Free PMC article.

7

Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin).

Klings ES, Hill NS, Ieong MH, Simms RW, Korn JH, Farber HW. Klings ES, et al. Among authors: farber hw. Arthritis Rheum. 1999 Dec;42(12):2638-45. doi: 10.1002/1529-0131(199912)42:12<2638::AID-ANR20>3.0.CO;2-X. Arthritis Rheum. 1999. PMID: 10616012 Free article.

8

Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.

Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Fisher KA, et al. Among authors: farber hw. Chest. 2006 Nov;130(5):1481-8. doi: 10.1378/chest.130.5.1481. Chest. 2006. PMID: 17099027

9

Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.

Menon AA, Sahay S, Braverman LE, Farber HW. Menon AA, et al. Among authors: farber hw. Lung. 2019 Dec;197(6):761-768. doi: 10.1007/s00408-019-00283-8. Epub 2019 Nov 6. Lung. 2019. PMID: 31696306

10

Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.

Farber HW, Graven KK, Kokolski G, Korn JH. Farber HW, et al. J Rheumatol. 1999 May;26(5):1195-6. J Rheumatol. 1999. PMID: 10332990

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

253 results

Search Page

Filters